Tags:BioTechCauseDevelopmentFamilyLifeMovingPharmacyPlatform
Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, atuzaginstat (COR388), has advanced through Phase Ib and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer’s disease patients.
Likes
98
Location: United States, California, South San Francisco
Member count: 11-50
Total raised: $92M
Founded date: 2012

Investors 5

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
31.05.2018Series B$76M-dolbyventu...
17.01.2016Series A$15M-finsmes.co...
06.10.2014Seed$1M-vcnewsdail...

Mentions in press and media 20

DateTitleDescriptionCategoryAuthorSource
09.12.2021Breakout V...Breakout Ventures, a San Franc...bioscience...Connie Loi...techcrunch...
11.11.2021Cortexyme ...Top-line Results from the GAIN...--marketscre...
14.07.2021Cortexyme ...A) Biofilms formed from a 106 ...--marketscre...
05.03.2021VC Lindy F...Deep science investor Lindy Fi...Breakout V...Connie Loi...techcrunch...
26.01.2021Cortexyme ...January 26, 2021 Disclaimer ...--marketscre...
02.07.2018These 50 f...On Friday, we featured 25 foun...alyssa rav...Connie Loi...techcrunch...
01.06.2018Term Sheet...NO NEW FUND Happy Friday, Ter...--fortune.co...
31.05.2018Cortexyme ... SOUTH SAN FRANCISCO, CA, Cor...--vcnewsdail...
31.05.2018Cortexyme ...---dolbyventu...
31.05.2018Cortexyme ...Cortexyme, Inc., a South San F...USA-finsmes.co...
Show more